Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Int J Radiat Oncol Biol Phys

Retrieve available abstracts of 298 articles:
HTML format



Single Articles


    July 2021
  1. PARZEN JS, Hamstra DA
    Patient-Reported Quality of Life During Prostate Cancer Radiation Therapy: Insights Into the Patient Experience.
    Int J Radiat Oncol Biol Phys. 2021;110:1129-1131.
    PubMed    


  2. CHOUDHURY A, Henry Md Frcr A, Mitin Md PhD T, Chen Md Mph R, et al
    Photons, Protons, SBRT, Brachytherapy-What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team.
    Int J Radiat Oncol Biol Phys. 2021;110:1114-1121.
    PubMed    


  3. EFSTATHIOU JA, Kamran SC, Spratt DE
    Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming.
    Int J Radiat Oncol Biol Phys. 2021;110:1098-1100.
    PubMed    


  4. SCHUMACHER O, Luo H, Taaffe DR, Galvao DA, et al
    Effects of exercise during radiotherapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2021 Jul 8. pii: S0360-3016(21)00841.
    PubMed     Abstract available


  5. BERTHOLD J, Khamfongkhruea C, Petzoldt J, Thiele J, et al
    First-in-human validation of CT-based proton range prediction using prompt gamma imaging in prostate-cancer treatments.
    Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00843.
    PubMed     Abstract available


  6. KISHAN AU, Collins SP
    Quality of Life After Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;110:727-730.
    PubMed    


  7. MOHAMAD O, Feng F
    Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome?
    Int J Radiat Oncol Biol Phys. 2021;110:634-635.
    PubMed    


  8. BELKACEMI Y, Coraggio G, Loganadane G
    Management Strategy of High-Risk Localized Prostate Cancer: Is there a Transatlantic Consensus?
    Int J Radiat Oncol Biol Phys. 2021;110:631-632.
    PubMed    


    May 2021
  9. NITHIYANANTHAN K, Creighton N, Currow D, Martin JM, et al
    Population-Level Uptake of Moderately Hypofractionated Definitive Radiotherapy in the Treatment of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 8. pii: S0360-3016(21)00460.
    PubMed     Abstract available


  10. HARA D, Tao W, Totiger T, Pourmand A, et al
    Prostate Cancer Targeted X-ray Fluorescence Imaging via Gold Nanoparticles Functionalized with Prostate-Specific Membrane Antigen (PSMA).
    Int J Radiat Oncol Biol Phys. 2021 May 5. pii: S0360-3016(21)00459.
    PubMed     Abstract available


    April 2021
  11. NABID A, Carrier N, Vigneault E, Van Nguyen T, et al
    OPTIMIZING TREATMENT IN INTERMEDIATE RISK PROSTATE CANCER: SECONDARY ANALYSIS OF A RANDOMIZED PHASE III TRIAL.
    Int J Radiat Oncol Biol Phys. 2021 Apr 23. pii: S0360-3016(21)00373.
    PubMed     Abstract available


  12. MASTERS SC, Hofling AA, Gorovets A, Marzella L, et al
    FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
    Int J Radiat Oncol Biol Phys. 2021 Apr 12. pii: S0360-3016(21)00357.
    PubMed    


  13. YAMAZAKI H, Suzuki G, Aibe N, Yoshida K, et al
    Posterior Margins in Prostate Cancer Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:1657-1658.
    PubMed    


  14. MITCHELL D, Jain S
    Brachytherapy Boost in Prostate Cancer: What Does Observational Data Add to the Debate?
    Int J Radiat Oncol Biol Phys. 2021;109:1230-1231.
    PubMed    


  15. LEITE ETT, Ramos CCA, Ribeiro VAB, Salvajoli BP, et al
    Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2021;109:1263-1270.
    PubMed     Abstract available


  16. FU SY, Chen FH, Wang CC, Yu CF, et al
    Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
    Int J Radiat Oncol Biol Phys. 2021;109:1547-1558.
    PubMed     Abstract available


  17. ROBIN S, Jolicoeur M, Palumbo S, Zilli T, et al
    Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:1243-1253.
    PubMed     Abstract available


    March 2021
  18. FOLKERT MR, Zelefsky MJ, Hannan R, Desai NB, et al
    A Multi-Institutional Phase II Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 19. pii: S0360-3016(21)00285.
    PubMed     Abstract available


  19. MAGLI A, Farneti A, Faiella A, Ferriero M, et al
    Toxicity at 1 year after Stereotactic Body Radiotherapy in 3 Fractions for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Mar 18. pii: S0360-3016(21)00287.
    PubMed     Abstract available


  20. BUSZEK SM, Ludmir EB, Grosshans DR, McAleer MF, et al
    Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Int J Radiat Oncol Biol Phys. 2021;109:718-725.
    PubMed     Abstract available


  21. SHAHI J, Poon I, Ung YC, Tsao M, et al
    Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Int J Radiat Oncol Biol Phys. 2021;109:764-774.
    PubMed     Abstract available


    February 2021
  22. BUBLEY GJ, Kaplan I, Bhatt R, Taplin ME, et al
    Phase II study of Enzalutamide with radiation therapy for intermediate risk prostate cancer: A phase 2 study.
    Int J Radiat Oncol Biol Phys. 2021 Feb 23. pii: S0360-3016(21)00205.
    PubMed     Abstract available


  23. KUBES J, Haas A, Vondracek V, Andrlik M, et al
    Ultra-hypofractionated proton radiotherapy in the treatment of low- and intermediate-risk prostate cancer - 5-years outcomes.
    Int J Radiat Oncol Biol Phys. 2021 Feb 12. pii: S0360-3016(21)00189.
    PubMed     Abstract available


  24. VAPIWALA N, Wong JK, Handorf E, Paly J, et al
    A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity-Modulated Radiation Therapy in Early Stage Prostate Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00117.
    PubMed     Abstract available


  25. SUD S, Gerringer BC, Wacaser B, Tan X, et al
    Under-ascertainment of clinically-meaningful symptoms during prostate cancer radiation therapy - does this vary by patient characteristics?
    Int J Radiat Oncol Biol Phys. 2021 Feb 1. pii: S0360-3016(21)00108.
    PubMed     Abstract available


    January 2021
  26. ROY S, Grimes S, Morgan SC, Eapen L, et al
    Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Jan 29. pii: S0360-3016(21)00092.
    PubMed     Abstract available


  27. CHEN RC, Prime SG, Basak R, Moon DH, et al
    Receipt of guideline-recommended surveillance in a population-based cohort of active surveillance prostate cancer patients.
    Int J Radiat Oncol Biol Phys. 2021 Jan 13. pii: S0360-3016(21)00034.
    PubMed     Abstract available


    December 2020
  28. GARIN O, Suarez JF, Guedea F, Pont A, et al
    Comparative Effectiveness Research in Localized Prostate Cancer: a 10-Year follow-up Cohort Study.
    Int J Radiat Oncol Biol Phys. 2020 Dec 31. pii: S0360-3016(20)34728.
    PubMed     Abstract available


  29. CHEN WC, Li Y, Lazar A, Altan A, et al
    Stereotactic body radiotherapy and high-dose rate brachytherapy boost in combination with intensity modulated radiotherapy for localized prostate cancer: a single-institution propensity score matched analysis.
    Int J Radiat Oncol Biol Phys. 2020 Dec 29. pii: S0360-3016(20)34730.
    PubMed     Abstract available


  30. TANG C, Lei X, Smith GL, Pan HY, et al
    Influence of Geography on Prostate Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2020 Dec 11. pii: S0360-3016(20)34595.
    PubMed     Abstract available


  31. PARRY MG, Nossiter J, Sujenthiran A, Cowling TE, et al
    Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study.
    Int J Radiat Oncol Biol Phys. 2020 Dec 3. pii: S0360-3016(20)34545.
    PubMed     Abstract available


  32. DEE EC, Muralidhar V, Arega MA, Kishan AU, et al
    Factors influencing non-completion of radiotherapy among men with localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Dec 1. pii: S0360-3016(20)34604.
    PubMed     Abstract available


  33. JANI A, Schreibmann E, Goyal S, Raghuveer H, et al
    Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine ((18)F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:1397.
    PubMed    


  34. MARCELLO M, Denham JW, Kennedy A, Haworth A, et al
    Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Int J Radiat Oncol Biol Phys. 2020;108:1304-1318.
    PubMed     Abstract available


    November 2020
  35. KOONTZ BF, Hoffman KE, Halabi S, Healy P, et al
    Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Nov 28. pii: S0360-3016(20)34599.
    PubMed     Abstract available


  36. WAGES NA, Sanders JC, Smith A, Wood S, et al
    Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial.
    Int J Radiat Oncol Biol Phys. 2020 Nov 20. pii: S0360-3016(20)34497.
    PubMed     Abstract available


  37. SPENCER KL, Tree AC
    Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:927-929.
    PubMed    


  38. DESAI NB, Garant A, Hannan R, Folkert MR, et al
    Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation.
    Int J Radiat Oncol Biol Phys. 2020;108:914-916.
    PubMed    


  39. BOHMER D, Hocht S, Wiegel T
    Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
    Int J Radiat Oncol Biol Phys. 2020;108:903-904.
    PubMed    


  40. SHI J, Xu K, Keyvanloo A, Udayakumar TS, et al
    A Multimodality Image Guided Precision Radiation Research Platform: Integrating X-ray, Bioluminescence, and Fluorescence Tomography With Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;108:1063-1072.
    PubMed     Abstract available


  41. TABRIZI S, Alshalalfa M, Mahal BA, Davicioni E, et al
    Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
    Int J Radiat Oncol Biol Phys. 2020;108:936-940.
    PubMed     Abstract available


  42. TAKAGI M, Demizu Y, Fujii O, D KT, et al
    Proton Therapy for Localized Prostate Cancer: Long-term Results in 2,021 Patients.
    Int J Radiat Oncol Biol Phys. 2020 Nov 10. pii: S0360-3016(20)34493.
    PubMed     Abstract available


  43. GOGINENI E, Rana Z, Soberman D, Sidiqi B, et al
    Biochemical control and toxicity outcomes of SBRT vs LDR brachytherapy in the treatment of low and intermediate risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Nov 7. pii: S0360-3016(20)34489.
    PubMed     Abstract available


  44. BERK L, Lopez Alfonso JC
    Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer In Regard to Vogelius et al.
    Int J Radiat Oncol Biol Phys. 2020;108:834.
    PubMed    


  45. THOMPSON AB, Hamstra DA
    Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:644-648.
    PubMed    


  46. VOGELIUS IR, Bentzen SM
    In Reply to Berk and Alfonso.
    Int J Radiat Oncol Biol Phys. 2020;108:834-835.
    PubMed    


  47. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
    Oligometastasis: Past, Present, Future.
    Int J Radiat Oncol Biol Phys. 2020;108:530-538.
    PubMed     Abstract available


  48. MAO X, Pineau J, Keyes R, Enger SA, et al
    RapidBrachyDL: Rapid Radiation Dose Calculations in Brachytherapy Via Deep Learning.
    Int J Radiat Oncol Biol Phys. 2020;108:802-812.
    PubMed     Abstract available


    October 2020
  49. HOFFMAN KE
    Wait and Hurry Up: Radiation Therapy for Prostate Cancer During the COVID-19 Pandemic.
    Int J Radiat Oncol Biol Phys. 2020;108:340.
    PubMed    


  50. LEEMAN JE, Nguyen PL
    Less Is More During COVID 19.
    Int J Radiat Oncol Biol Phys. 2020;108:339.
    PubMed    


  51. SPRATT DE
    Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion.
    Int J Radiat Oncol Biol Phys. 2020;108:338-339.
    PubMed    


  52. MOHAMAD O, Roach M 3rd
    Delaying Dilemmas: Coronavirus Complications Impacting the Management of Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:337.
    PubMed    


  53. LING DC, Vargo JA, Beriwal S
    Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
    Int J Radiat Oncol Biol Phys. 2020;108:390-393.
    PubMed    


  54. ZAORSKY NG
    Prostate and Pelvis on Pause Pending a Pandemic.
    Int J Radiat Oncol Biol Phys. 2020;108:341-342.
    PubMed    


  55. KOONTZ BF
    Through COVID-Colored Glasses: New Perspectives on Same Data.
    Int J Radiat Oncol Biol Phys. 2020;108:338.
    PubMed    


    September 2020
  56. SANDERS JW, Venkatesan AM, Levitt CA, Bathala T, et al
    Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study.
    Int J Radiat Oncol Biol Phys. 2020 Sep 24. pii: S0360-3016(20)34342.
    PubMed     Abstract available


  57. SPRATT DE, Tward JD
    Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
    Int J Radiat Oncol Biol Phys. 2020 Sep 11. pii: S0360-3016(20)31252.
    PubMed    


  58. ROYCE TJ, Mavroidis P, Wang K, Falchook AD, et al
    Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Sep 5. pii: S0360-3016(20)34102.
    PubMed     Abstract available



  59. Erratum to: Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel VN, Wu XD, Reis I, Studenski MT, Casillas J, Stoyanova R. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Rad
    Int J Radiat Oncol Biol Phys. 2020;108:328.
    PubMed    


    August 2020
  60. HALL WA, Paulson E, Davis BJ, Spratt DE, et al
    NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 27. pii: S0360-3016(20)34124.
    PubMed     Abstract available


  61. DEEK MP, Taparra K, Dao D, Chan L, et al
    Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 13. pii: S0360-3016(20)34120.
    PubMed     Abstract available


  62. PALY J, Horwitz EM
    Less Is More: Treatment of Locally Advanced Small Cell Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;107:865-866.
    PubMed    


  63. DALWADI SM, Zhu A
    Big Small Cell Dilemma.
    Int J Radiat Oncol Biol Phys. 2020;107:863-864.
    PubMed    


  64. ABU-GHEIDA I, Bathala TK, Maldonado JA, Khan M, et al
    Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers.
    Int J Radiat Oncol Biol Phys. 2020;107:982-985.
    PubMed     Abstract available


    July 2020
  65. PARRY MG, Nossiter J, Cowling TE, Sujenthiran A, et al
    Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes.
    Int J Radiat Oncol Biol Phys. 2020 Jul 24. pii: S0360-3016(20)31450.
    PubMed     Abstract available


  66. MITIN T, Choudhury A
    Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation.
    Int J Radiat Oncol Biol Phys. 2020;107:609-612.
    PubMed    


  67. WANG Y, Chen H
    In Reply to Ghadjar et al.
    Int J Radiat Oncol Biol Phys. 2020;107:856.
    PubMed    


  68. MYLONA E, Ebert M, Kennedy A, Joseph D, et al
    Rectal and Urethro-vesical Subregions for Toxicity Prediction After Prostate Cancer Radiotherapy: validation of voxel-based models in an independent population.
    Int J Radiat Oncol Biol Phys. 2020 Jul 13. pii: S0360-3016(20)31417.
    PubMed     Abstract available


  69. BERGAMIN S, Eade T, Kneebone A, Booth J, et al
    Interim results of a prospective PSMA-directed focal stereotactic re-irradiation trial for locally recurrent prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jul 10. pii: S0360-3016(20)31412.
    PubMed     Abstract available


  70. SANDERS JW, Lewis GD, Thames HD, Kudchadker RJ, et al
    Machine segmentation of pelvic anatomy in MRI-assisted radiosurgery (MARS) for prostate cancer brachytherapy.
    Int J Radiat Oncol Biol Phys. 2020 Jul 4. pii: S0360-3016(20)31396.
    PubMed     Abstract available


  71. VAN SCHIE MA, Janssen TM, Eekhout D, Walraven I, et al
    Knowledge-based assessment of focal dose escalation treatment plans in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jul 3. pii: S0360-3016(20)31392.
    PubMed     Abstract available


    June 2020
  72. ROY S, Grimes S, Eapen L, Spratt DE, et al
    Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 18. pii: S0360-3016(20)31258.
    PubMed     Abstract available


  73. PARIKH NR, Kishan AU, Kane N, Diaz-Perez S, et al
    Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 17. pii: S0360-3016(20)31251.
    PubMed     Abstract available


  74. PARIKH NR, Chang EM, Nickols NG, Rettig MB, et al
    Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jun 13. pii: S0360-3016(20)31250.
    PubMed     Abstract available


  75. JACCARD M, Zilli T, Dubouloz A, Escude L, et al
    Urethra-sparing stereotactic body radiotherapy for prostate cancer: quality assuranceof a randomized phase II trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 11. pii: S0360-3016(20)31242.
    PubMed     Abstract available


  76. KOLLMEIER MA, McBride S, Varghese M, Debonis D, et al
    Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: Results from a prospective trial.
    Int J Radiat Oncol Biol Phys. 2020 Jun 4. pii: S0360-3016(20)31189.
    PubMed    



  77. Erratum to: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. A Prospective Study of 18F-DCFPyL PSMA PET/CT Res
    Int J Radiat Oncol Biol Phys. 2020;107:390.
    PubMed    


  78. YUCE SARI S, Elmali A, Arslan S, Ozyigit G, et al
    In Regard to Aksnessaetheret al.
    Int J Radiat Oncol Biol Phys. 2020;107:387-388.
    PubMed    


  79. CHIN S, Fatimilehin A, Walshaw R, Argarwal A, et al
    Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
    Int J Radiat Oncol Biol Phys. 2020;107:288-296.
    PubMed     Abstract available


    May 2020
  80. GHADJAR P, Zwahlen DR, Hayoz S, Aebersold DM, et al
    In Regard to Qi et al.
    Int J Radiat Oncol Biol Phys. 2020;107:224-225.
    PubMed    


  81. GUNTHER JR
    Involved-Site Radiation Therapy if Minimal Toxicity.
    Int J Radiat Oncol Biol Phys. 2020;107:20-21.
    PubMed    


  82. ALAYED Y, Davidson M, Liu S, Chu W, et al
    Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
    Int J Radiat Oncol Biol Phys. 2020;107:136-142.
    PubMed     Abstract available


    April 2020
  83. QIN H, Zhang V, Bok RA, Santos RD, et al
    Simultaneous metabolic and perfusion imaging using hyperpolarized (13)C MRI can evaluate early and dose-dependent responses to radiotherapy in a prostate cancer mouse model.
    Int J Radiat Oncol Biol Phys. 2020 Apr 24. pii: S0360-3016(20)31042.
    PubMed     Abstract available


  84. MCCLELLAND S 3RD, Petereit DG
    The Advanced Alternative Payment Model: Catalyst for Prostate Brachytherapy Adoption?
    Int J Radiat Oncol Biol Phys. 2020;106:1104-1105.
    PubMed    


  85. WILKINS A, Naismith O, Brand D, Fernandez K, et al
    Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
    Int J Radiat Oncol Biol Phys. 2020;106:928-938.
    PubMed     Abstract available


    March 2020
  86. KEALL P, Nguyen DT, O'Brien R, Hewson E, et al
    Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy: Results from the TROG 15.01 SPARK Trial.
    Int J Radiat Oncol Biol Phys. 2020 Mar 29. pii: S0360-3016(20)30937.
    PubMed     Abstract available


  87. DESS RT
    Treatment Intensification in High-Risk Prostate Cancer: Lessons From the TROG 03.04 RADAR Trial.
    Int J Radiat Oncol Biol Phys. 2020;106:703-705.
    PubMed    


  88. JOSEPH D, Denham JW, Steigler A, Lamb DS, et al
    Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.
    Int J Radiat Oncol Biol Phys. 2020;106:693-702.
    PubMed     Abstract available


  89. ACHARD V, Zilli T
    In Regard to Qi et al.
    Int J Radiat Oncol Biol Phys. 2020;106:887-888.
    PubMed    


  90. KOONTZ BF, Pra AD
    Shifting the Curtain-Can We Make Sense of the Whole Pelvis Controversy?
    Int J Radiat Oncol Biol Phys. 2020;106:534-536.
    PubMed    


  91. HAGAN M, Kapoor R, Michalski J, Sandler H, et al
    VA-Radiation Oncology Quality Surveillance Program.
    Int J Radiat Oncol Biol Phys. 2020;106:639-647.
    PubMed     Abstract available


  92. SAMPATH S, Frankel P, Vecchio BD, Ruel N, et al
    Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial.
    Int J Radiat Oncol Biol Phys. 2020;106:537-545.
    PubMed     Abstract available


  93. VITZTHUM LK, Park H, Zakeri K, Heide ES, et al
    Risk of Pelvic Fracture With Radiation Therapy in Older Patients.
    Int J Radiat Oncol Biol Phys. 2020;106:485-492.
    PubMed     Abstract available


    February 2020
  94. SUN L, Smith W, Kirkby C
    Variation in Inter-institutional Plan Quality When Adopting A Hypofractionated Protocol for Prostate Cancer External Beam Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020 Feb 26. pii: S0360-3016(20)30252.
    PubMed     Abstract available


  95. AKSNESSAETHER BY, Myklebust TA, Solberg A, Klepp OH, et al
    "Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial."
    Int J Radiat Oncol Biol Phys. 2020 Feb 26. pii: S0360-3016(20)30253.
    PubMed    


  96. POLLACK A, Chinea FM, Bossart E, Kwon D, et al
    PHASE i TRIAL OF MRI-GUIDED Prostate Cancer Lattice Extreme Ablative Dose (LEAD) BOOST Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2020 Feb 18. pii: S0360-3016(20)30218.
    PubMed     Abstract available


  97. SCARSBROOK AF, Bottomley D, Teoh EJ, Bradley KM, et al
    Impact of (18)F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial.
    Int J Radiat Oncol Biol Phys. 2020 Feb 14. pii: S0360-3016(20)30203.
    PubMed     Abstract available


  98. DINH TT, Lee HJ Jr, Macomber MW, Apisarnthanarax S, et al
    Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared To Rectal Balloon Immobilization After Proton Beam Radiotherapy For Localized Prostate Cancer: A Retrospective Observational Study.
    Int J Radiat Oncol Biol Phys. 2020 Feb 5. pii: S0360-3016(20)30152.
    PubMed     Abstract available


  99. LIN J, Den RB, Greenspan J, Showalter TN, et al
    Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Feb 3. pii: S0360-3016(19)34522.
    PubMed     Abstract available


  100. TENDULKAR RD, Mian OY
    Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable.
    Int J Radiat Oncol Biol Phys. 2020;106:238.
    PubMed    


  101. BALLAS LK
    Nodal Recurrence From Prostate Adenocarcinoma: Curable.
    Int J Radiat Oncol Biol Phys. 2020;106:238-239.
    PubMed    


  102. RODRIGUEZ-LOPEZ JL, Beriwal S
    Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?
    Int J Radiat Oncol Biol Phys. 2020;106:236-237.
    PubMed    


  103. CORNELL M, Kaderka R, Hild SJ, Ray XJ, et al
    Noninferiority Study of Automated Knowledge-Based Planning Versus Human-Driven Optimization Across Multiple Disease Sites.
    Int J Radiat Oncol Biol Phys. 2020;106:430-439.
    PubMed     Abstract available


  104. FULLER D, Wurzer J, Shirazi R, Bridge S, et al
    Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
    Int J Radiat Oncol Biol Phys. 2020;106:291-299.
    PubMed     Abstract available


    January 2020
  105. VAN SON MJ, Peters M, Moerland MA, Lagendijk JJW, et al
    MRI-guided ultrafocal salvage high-dose-rate brachytherapy for localized radiorecurrent prostate cancer: updated results of 50 patients.
    Int J Radiat Oncol Biol Phys. 2020 Jan 29. pii: S0360-3016(20)30129.
    PubMed     Abstract available


  106. RASMUSSON E, Gunnlaugsson A, Wieslander E, Hoglund P, et al
    Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing ultra-hypofractionated and conventionally fractionated radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jan 28. pii: S0360-3016(20)30128.
    PubMed     Abstract available


  107. VOGELIUS IR, Bentzen SM
    Diminishing returns from ultra-hypofractionated radiation therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jan 24. pii: S0360-3016(20)30069.
    PubMed     Abstract available


  108. KANG J, Thompson RF, Fuller CD, Camphausen KA, et al
    In Regard to Wallner et al.
    Int J Radiat Oncol Biol Phys. 2020;106:217-218.
    PubMed    


  109. MARPLES B, Wilson GD
    Predicting Outcome using Genomic-Based Liquid Biomarkers.
    Int J Radiat Oncol Biol Phys. 2020;106:1-4.
    PubMed    


  110. NOSRATI R, Wronski M, Tseng CL, Chung H, et al
    Postimplant Dosimetry of Permanent Prostate Brachytherapy: Comparison of MRI-Only and CT-MRI Fusion-Based Workflows.
    Int J Radiat Oncol Biol Phys. 2020;106:206-215.
    PubMed     Abstract available


  111. ONG WL, Foroudi F, Milne RL, Millar JL, et al
    Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia.
    Int J Radiat Oncol Biol Phys. 2020;106:61-66.
    PubMed     Abstract available


    December 2019
  112. MURRAY JR, Tree AC, Alexander E, Sohaib A, et al
    Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: efficacy and toxicity in the DELINEATE trial.
    Int J Radiat Oncol Biol Phys. 2019 Dec 5. pii: S0360-3016(19)34461.
    PubMed     Abstract available


  113. HENRY A
    Using Multiparametric Magnetic Resonance Imaging to Shift Prostate Cancer Diagnosis Toward Clinically Significant Disease and Minimize Overdiagnosis (and Overtreatment).
    Int J Radiat Oncol Biol Phys. 2019;105:915-917.
    PubMed    


  114. LARGENT A, Barateau A, Nunes JC, Mylona E, et al
    Comparison of Deep Learning-Based and Patch-Based Methods for Pseudo-CT Generation in MRI-Based Prostate Dose Planning.
    Int J Radiat Oncol Biol Phys. 2019;105:1137-1150.
    PubMed     Abstract available


    November 2019
  115. AKSNESSAETHER BY, Myklebust TA, Solberg A, Klepp OH, et al
    Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial.
    Int J Radiat Oncol Biol Phys. 2019 Nov 28. pii: S0360-3016(19)34066.
    PubMed     Abstract available


  116. THORNQVIST S 2ND, Abal B, Ovrelid KS, Engeseth GM, et al
    Plan selection in proton therapy of locally advanced prostate cancer with simultaneous treatment of multiple targets.
    Int J Radiat Oncol Biol Phys. 2019 Nov 20. pii: S0360-3016(19)34005.
    PubMed     Abstract available


  117. QUINN TJ, Hamstra D
    Hypofractionation in Prostate Cancer Using Proton Beam.
    Int J Radiat Oncol Biol Phys. 2019;105:723-726.
    PubMed    


  118. LIU W, Zukotynski K, Emmett L, Chung HT, et al
    A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2019 Nov 12. pii: S0360-3016(19)33971.
    PubMed     Abstract available


  119. MITIN T, Henry A, Choudhury A, Chen RC, et al
    SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?
    Int J Radiat Oncol Biol Phys. 2019;105:618-620.
    PubMed    


  120. JIANG NY, Dang AT, Yuan Y, Chu FI, et al
    Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;105:628-636.
    PubMed     Abstract available


  121. BIRD D, Henry AM, Sebag-Montefiore D, Buckley DL, et al
    A Systematic Review of the Clinical Implementation of Pelvic Magnetic Resonance Imaging-Only Planning for External Beam Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;105:479-492.
    PubMed     Abstract available


    October 2019
  122. QI X, Gao XS, Li HZ, Qin SB, et al
    Toxicity and Biochemical Outcomes of Dose-Intensified Post-Operative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial.
    Int J Radiat Oncol Biol Phys. 2019 Oct 25. pii: S0360-3016(19)33948.
    PubMed     Abstract available


  123. THARMALINGAM H, Tsang Y, Choudhury A, Alonzi R, et al
    External beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume.
    Int J Radiat Oncol Biol Phys. 2019 Oct 11. pii: S0360-3016(19)33877.
    PubMed     Abstract available


  124. PASQUIER D, Peiffert D, Nickers P, Maingon P, et al
    A multicentre phase II study of hypofractionated stereostatic boost in intermediate risk prostate carcinoma: a 5-year analysis of the CKNO-PRO trial.
    Int J Radiat Oncol Biol Phys. 2019 Oct 8. pii: S0360-3016(19)33863.
    PubMed     Abstract available


  125. DE VRIES KC, Wortel RC, Hoop EO, Heemsbergen WD, et al
    Hyprofractionated versus conventionally fractionated radiotherapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multi-centre, open-label, phase 3 HYPRO trial.
    Int J Radiat Oncol Biol Phys. 2019 Oct 5. pii: S0360-3016(19)33827.
    PubMed     Abstract available


    August 2019
  126. BRUYNZEEL AME, Tetar SU, Oei SS, Senan S, et al
    A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results.
    Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33640.
    PubMed     Abstract available


  127. DEEK MP, Yu C, Phillips R, Song DY, et al
    Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.
    Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33641.
    PubMed     Abstract available


  128. MOON DH, Chen RC
    Partial Prostate Cancer Treatment for Aggressive Disease-Common Practice.
    Int J Radiat Oncol Biol Phys. 2019;104:1035-1037.
    PubMed    


  129. MARVASO G, Ciardo D, Gandini S, Riva G, et al
    Comparison of outcomes and toxicity between extreme and moderate radiotherapy hypofractionation in localized prostate cancer: a propensity score analysis.
    Int J Radiat Oncol Biol Phys. 2019 Aug 1. pii: S0360-3016(19)33531.
    PubMed     Abstract available


  130. JULIET VAN SON M, Peters M, Moerland MA, van der Voort van Zyp JRN, et al
    In Reply to David and Kamrava.
    Int J Radiat Oncol Biol Phys. 2019;104:1183-1184.
    PubMed    


  131. DAVID J, Kamrava M
    In Regard to Peters et al.
    Int J Radiat Oncol Biol Phys. 2019;104:1182-1183.
    PubMed    


  132. MORTON GC, Hoskin PJ
    Single Fraction High-Dose-Rate Brachytherapy: Too Good to Be True?
    Int J Radiat Oncol Biol Phys. 2019;104:1054-1056.
    PubMed    


  133. HAWKEN SR, Spratt DE, Qi J, Linsell SM, et al
    Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2019;104:1030-1034.
    PubMed     Abstract available


    July 2019
  134. TAPROGGE J, Murray I, Gear J, Chittenden SJ, et al
    Title: Compartmental model for (223)Ra-Dichloride in patients with metastatic bone disease from castration-resistant prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jul 23. pii: S0360-3016(19)33505.
    PubMed     Abstract available


  135. PASQUIER D, Martinage G, Janoray G, Rojas DP, et al
    Salvage stereotactic body radiotherapy for local prostate cancer recurrence after radiotherapy: a retrospective multicentre study of the GETUG.
    Int J Radiat Oncol Biol Phys. 2019 Jul 22. pii: S0360-3016(19)33494.
    PubMed     Abstract available


  136. SPRATT DE, Michalski JM
    Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:798-800.
    PubMed    


  137. LIU C, Gardner SJ, Wen N, Elshaikh MA, et al
    Automatic Segmentation of the Prostate on CT Images Using Deep Neural Networks (DNN).
    Int J Radiat Oncol Biol Phys. 2019;104:924-932.
    PubMed     Abstract available


  138. PASALIC D, Kuban DA, Allen PK, Tang C, et al
    Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2019;104:790-797.
    PubMed     Abstract available


  139. MURALIDHAR V, Zhang J, Wang Q, Mahal BA, et al
    Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jul 1. pii: S0360-3016(19)33398.
    PubMed     Abstract available


    June 2019
  140. OSMAN SO, Leijenaar RT, Cole AJ, Lyons CA, et al
    CT-based Radiomics for Risk Stratification in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 26. pii: S0360-3016(19)33392.
    PubMed     Abstract available


  141. YOSHIDA S, Takahara T, Arita Y, Ishii C, et al
    Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor.
    Int J Radiat Oncol Biol Phys. 2019 Jun 12. pii: S0360-3016(19)30837.
    PubMed     Abstract available


  142. LEUFGENS F, Berneking V, Vogeli TA, Kirschner-Hermanns R, et al
    Quality of life changes >10 years following postoperative radiotherapy after radical prostatectomy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 12. pii: S0360-3016(19)30829.
    PubMed     Abstract available


  143. GREWAL AS, Schonewolf C, Min EJ, Chao HH, et al
    Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 11. pii: S0360-3016(19)30827.
    PubMed     Abstract available


  144. JACKSON IL, Pavlovic R, Alexander AA, Connors CQ, et al
    BIO 300, a nanosuspension of genistein, mitigates radiation-induced erectile dysfunction and sensitizes human prostate cancer xenografts to radiation therapy.
    Int J Radiat Oncol Biol Phys. 2019 Jun 5. pii: S0360-3016(19)30816.
    PubMed     Abstract available


  145. SANDLER HM
    Responding to Information From Novel Positron Emission Tomography Imaging in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:263-264.
    PubMed    


  146. MENZEL P, Chang A
    Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;104:261-262.
    PubMed    


  147. SPRATT DE
    What Are We Even Looking At?
    Int J Radiat Oncol Biol Phys. 2019;104:264-265.
    PubMed    


  148. LI YR, Roach M 3rd
    Stampede to Cure.
    Int J Radiat Oncol Biol Phys. 2019;104:264.
    PubMed    


  149. MITO JK, Mitra D, Barysauskas CM, Marino-Enriquez A, et al
    A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas.
    Int J Radiat Oncol Biol Phys. 2019;104:425-435.
    PubMed     Abstract available


    May 2019
  150. YUAN Y, Aghdam N, King C, Fuller D, et al
    Testosterone Levels and Sexual Quality of Life Following Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials.
    Int J Radiat Oncol Biol Phys. 2019 May 17. pii: S0360-3016(19)30727.
    PubMed     Abstract available


  151. FERNANDES CD, Simoes R, Ghobadi G, Heijmink SW, et al
    Multi-parametric MRI tumor probability model for the detection of locally recurrent prostate cancer after radiotherapy: pathological validation and comparison with manual tumor delineations.
    Int J Radiat Oncol Biol Phys. 2019 May 11. pii: S0360-3016(19)30703.
    PubMed     Abstract available


  152. CHOUDHURY A, Chen RC, Henry A, Mistry H, et al
    STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2019;104:33-35.
    PubMed    



  153. Erratum to: Wilkins AC, Gusterson B, Szijgyarto Z, et al. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2018;101:309-315
    Int J Radiat Oncol Biol Phys. 2019;104:226.
    PubMed    


  154. BRYANT AK, Rose BS
    In Reply to Hurmuz and Ozyigit.
    Int J Radiat Oncol Biol Phys. 2019;104:225.
    PubMed    


  155. HURMUZ P, Ozyigit G
    In Regard to Bryant et al.
    Int J Radiat Oncol Biol Phys. 2019;104:224-225.
    PubMed    


  156. BALLAS LK, Luo C, Chung E, Kishan AU, et al
    Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2019;104:50-60.
    PubMed     Abstract available


    April 2019
  157. ALAYED Y, Loblaw A, Chu W, Al-Hanaqta M, et al
    Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study.
    Int J Radiat Oncol Biol Phys. 2019 Apr 16. pii: S0360-3016(19)30624.
    PubMed     Abstract available


  158. HALLEMEIER CL, Zhang P, Pisansky TM, Hanks GE, et al
    Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials.
    Int J Radiat Oncol Biol Phys. 2019 Apr 5. pii: S0360-3016(19)30610.
    PubMed     Abstract available


  159. JACKSON WC, Silva J, Hartman HE, Dess RT, et al
    Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
    Int J Radiat Oncol Biol Phys. 2019 Apr 5. pii: S0360-3016(19)30612.
    PubMed     Abstract available


  160. SONI PD
    Selection Bias in Population Registry-Based Comparative Effectiveness Research.
    Int J Radiat Oncol Biol Phys. 2019;103:1058-1060.
    PubMed    


    March 2019
  161. PETERS M, van Son MJ, Moerland MA, Kerkmeijer LGW, et al
    MRI-guided ultrafocal HDR-brachytherapy for localised prostate cancer: median 4 year results of a feasibility study.
    Int J Radiat Oncol Biol Phys. 2019 Mar 26. pii: S0360-3016(19)30399.
    PubMed     Abstract available


  162. MCCARTHY M, Francis R, Tang C, Watts J, et al
    A multicentre prospective clinical trial of (68)Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution, compared to standard imaging.
    Int J Radiat Oncol Biol Phys. 2019 Mar 16. pii: S0360-3016(19)30370.
    PubMed     Abstract available


  163. CICCHETTI A, Fiorino C, Rancati T, Valdagni R, et al
    In Reply to Loganadane et al.
    Int J Radiat Oncol Biol Phys. 2019;103:777-778.
    PubMed    


  164. LOGANADANE G, Coraggio G, Belkacemi Y
    In Regard to Cicchetti et al.
    Int J Radiat Oncol Biol Phys. 2019;103:776-777.
    PubMed    


  165. PARIKH RR
    Aggressive Focal Therapy.
    Int J Radiat Oncol Biol Phys. 2019;103:546.
    PubMed    


    February 2019
  166. D'AGOSTINO GR, di Brina L, Mancosu P, Franzese C, et al
    Re-Irradiation of Locally Recurrent Prostate Cancer with Volumetric Modulated Arc Therapy (Vmat).
    Int J Radiat Oncol Biol Phys. 2019 Feb 27. pii: S0360-3016(19)30285.
    PubMed     Abstract available


  167. SIDDIQUI ZA, Gustafson GS, Ye H, Martinez AA, et al
    5-Year Outcomes of a Single Institution Prospective Trial of 19 Gy Single-Fraction HDR Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 13. pii: S0360-3016(19)30205.
    PubMed     Abstract available


  168. POTTERS L, Rana Z, Lee L, Cox BW, et al
    Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II trial for Patients with Low and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 2. pii: S0360-3016(19)30183.
    PubMed     Abstract available


  169. ABU-GHEIDA I, Reddy CA, Kotecha R, Weller MA, et al
    Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiotherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 2. pii: S0360-3016(19)30182.
    PubMed     Abstract available


  170. MITIN T, Nguyen PL
    Postoperative Radiation Therapy in Localized Prostate Cancer: When, How Much, and How Fast?
    Int J Radiat Oncol Biol Phys. 2019;103:289-292.
    PubMed    


  171. MYLONA E, Acosta O, Lizee T, Lafond C, et al
    Voxel-based analysis for identification of urethro-vesical subregions predicting urinary toxicity after prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys. 2019 Feb 1. pii: S0360-3016(19)30179.
    PubMed     Abstract available


  172. YU JB, Beck TF, Anscher MS, Baschnagel AM, et al
    The ASTRO Research Portfolio: Where Do We Go From Here?
    Int J Radiat Oncol Biol Phys. 2019;103:308-309.
    PubMed    


  173. LARGENT A, Barateau A, Nunes JC, Lafond C, et al
    Pseudo-CT Generation for MRI-Only Radiation Therapy Treatment Planning: Comparison Among Patch-Based, Atlas-Based, and Bulk Density Methods.
    Int J Radiat Oncol Biol Phys. 2019;103:479-490.
    PubMed     Abstract available


  174. MOUNTRIS KA, Visvikis D, Bert J
    DVH-Based Inverse Planning Using Monte Carlo Dosimetry for LDR Prostate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2019;103:503-510.
    PubMed     Abstract available


  175. HERRERA FG, Valerio M, Berthold D, Tawadros T, et al
    50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Int J Radiat Oncol Biol Phys. 2019;103:320-334.
    PubMed     Abstract available


    January 2019
  176. GLICKSMAN R, Sanmamed N, Thoms J, Zlotta AR, et al
    A phase I pilot study of pre-operative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.
    Int J Radiat Oncol Biol Phys. 2019 Jan 6. pii: S0360-3016(19)30001.
    PubMed     Abstract available


  177. ZELEFSKY MJ, Kollmeier M, McBride S, Varghese M, et al
    5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients with Low and Intermediate Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jan 3. pii: S0360-3016(18)34227.
    PubMed     Abstract available


  178. ZUMSTEG ZS, Spratt DE
    Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?
    Int J Radiat Oncol Biol Phys. 2019;103:92-94.
    PubMed    


  179. BERLIN A, Murgic J, Hosni A, Pintilie M, et al
    Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.
    Int J Radiat Oncol Biol Phys. 2019;103:84-91.
    PubMed     Abstract available


  180. SALDI S, Bellavita R, Lancellotta V, Palumbo I, et al
    Acute Toxicity Profiles of Hypofractionated Adjuvant and Salvage Radiation Therapy After Radical Prostatectomy: Results of a Prospective Study.
    Int J Radiat Oncol Biol Phys. 2019;103:105-111.
    PubMed     Abstract available


    December 2018
  181. VAUGIER L, Palpacuer C, Rio E, Goineau A, et al
    Early toxicity of a phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07).
    Int J Radiat Oncol Biol Phys. 2018 Dec 14. pii: S0360-3016(18)34186.
    PubMed     Abstract available


  182. BRYANT AK, McKay RR, Kader AK, Parsons JK, et al
    Sub-castrate testosterone nadir and clinical outcomes in intermediate or high-risk localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2018 Dec 10. pii: S0360-3016(18)34080.
    PubMed     Abstract available


  183. DEARNALEY D, Griffin CL, Lewis R, Mayles P, et al
    Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
    Int J Radiat Oncol Biol Phys. 2018 Dec 6. pii: S0360-3016(18)33854.
    PubMed     Abstract available


    November 2018
  184. WORTEL RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, et al
    Moderate hypofractionation in intermediate and high risk, localized prostate cancer: Health-related quality of life from the randomized, phase 3 HYPRO trial.
    Int J Radiat Oncol Biol Phys. 2018 Nov 17. pii: S0360-3016(18)34006.
    PubMed     Abstract available


  185. ALAYED Y, Cheung P, Vesprini D, Liu S, et al
    SABR in high risk prostate cancer: outcomes from two prospective clinical trials with and without elective nodal irradiation.
    Int J Radiat Oncol Biol Phys. 2018 Nov 13. pii: S0360-3016(18)33997.
    PubMed     Abstract available


  186. SPIEGEL DY, Hong JC, Oyekunle T, Waters L, et al
    A Nomogram for Testosterone Recovery Following Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Nov 9. pii: S0360-3016(18)33954.
    PubMed     Abstract available


  187. SPRATT DE
    Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018;102:556-560.
    PubMed    


  188. MURGIC J, Morton G, Loblaw A, D'Alimonte L, et al
    Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2018;102:561-567.
    PubMed     Abstract available


    October 2018
  189. CARLES J, Gallardo E, Domenech M, Font A, et al
    Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.
    Int J Radiat Oncol Biol Phys. 2018 Oct 12. pii: S0360-3016(18)33856.
    PubMed     Abstract available


  190. CROOK JM, Zhang P, Pisansky TM, Trabulsi EJ, et al
    A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526).
    Int J Radiat Oncol Biol Phys. 2018 Oct 9. pii: S0360-3016(18)33830.
    PubMed     Abstract available


  191. MEIER RM, Bloch DA, Cotrutz C, Beckman AC, et al
    Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
    Int J Radiat Oncol Biol Phys. 2018;102:296-303.
    PubMed     Abstract available


    September 2018
  192. EVANS JD, Morris LK, Zhang H, Cao S, et al
    Prospective Immunophenotyping of CD8(+) T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed SBRT.
    Int J Radiat Oncol Biol Phys. 2018 Sep 8. pii: S0360-3016(18)33725.
    PubMed     Abstract available


  193. SOLDATOV A, von Klot CAJ, Walacides D, Derlin T, et al
    Patterns of progression after (68)Ga-PSMA-ligand PET/CT-guided radiotherapy for recurrent prostate cancer.
    Int J Radiat Oncol Biol Phys. 2018 Sep 7. pii: S0360-3016(18)33708.
    PubMed     Abstract available


  194. LEE DJ, Barocas DA, Zhao Z, Huang LC, et al
    Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018;102:116-126.
    PubMed     Abstract available


    August 2018
  195. OLSSON CE, Jackson A, Deasy JO, Thor M, et al
    A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys. 2018 Aug 17. pii: S0360-3016(18)33546.
    PubMed     Abstract available


  196. HOLMES JA, Anderson RF, Hoffman LG, Showalter TN, et al
    Cardiovascular Preventive Care and Coordination Of Care In Prostate Cancer Survivors: A Multi-Institutional Prospective Study.
    Int J Radiat Oncol Biol Phys. 2018 Aug 9. pii: S0360-3016(18)33519.
    PubMed     Abstract available


  197. PEARLSTEIN KA, Basak R, Chen RC
    Comparative effectiveness of prostate cancer treatment options: limitations of retrospective analysis of cancer registry data.
    Int J Radiat Oncol Biol Phys. 2018 Aug 9. pii: S0360-3016(18)33529.
    PubMed     Abstract available


  198. CARRARA M, Massari E, Cicchetti A, Giandini T, et al
    Development of a "ready to use" graphical tool based on artificial neural network classification: application for the prediction of late fecal incontinence after prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys. 2018 Aug 6. pii: S0360-3016(18)33482.
    PubMed     Abstract available


  199. ADAMS Q, Hopfensperger KM, Kim Y, Wu X, et al
    Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.
    Int J Radiat Oncol Biol Phys. 2018 Aug 6. pii: S0360-3016(18)33483.
    PubMed     Abstract available


  200. NGUYEN PL
    The Long and Short of It: New Lessons on the Optimal Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer and Where We Need to Go From Here.
    Int J Radiat Oncol Biol Phys. 2018;101:1014-1017.
    PubMed    


    July 2018
  201. DE CREVOISIER R, Bayar MA, Pommier P, Muracciole X, et al
    Daily versus weekly prostate cancer image-guided radiotherapy: Phase 3 multicenter randomized trial.
    Int J Radiat Oncol Biol Phys. 2018 Jul 30. pii: S0360-3016(18)33463.
    PubMed     Abstract available


  202. MUSUNURU HB, D'Alimonte L, Davidson M, Ho L, et al
    Phase I/II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients with High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.
    Int J Radiat Oncol Biol Phys. 2018 Jul 30. pii: S0360-3016(18)33462.
    PubMed     Abstract available


  203. EADE T, Choudhury A, Pollack A, Abramowitz M, et al
    Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study.
    Int J Radiat Oncol Biol Phys. 2018;101:957-963.
    PubMed     Abstract available


  204. SPRATT DE
    Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018;101:513-515.
    PubMed    


    June 2018
  205. CICCHETTI A, Avuzzi B, Palorini F, Ballarini F, et al
    Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation.
    Int J Radiat Oncol Biol Phys. 2018 Jun 30. pii: S0360-3016(18)30806.
    PubMed     Abstract available


  206. LUKKA HR, Pugh SL, Bruner DW, Bahary JP, et al
    Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2018 Jun 15. pii: S0360-3016(18)30961.
    PubMed     Abstract available


    May 2018
  207. LEE S, Kerns S, Ostrer H, Rosenstein B, et al
    Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2018;101:128-135.
    PubMed     Abstract available


    April 2018
  208. MCGARRY SD, Hurrell SL, Iczkowski KA, Hall W, et al
    Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Apr 24. pii: S0360-3016(18)30701.
    PubMed     Abstract available


  209. GOMEZ-ITURRIAGA A, Casquero F, Pijoan JI, Crook J, et al
    Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Apr 22. pii: S0360-3016(18)30696.
    PubMed     Abstract available


  210. BRYANT AK, Kader AK, McKay RR, Einck JP, et al
    Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Apr 17. pii: S0360-3016(18)30680.
    PubMed     Abstract available


  211. WILSON JM, Dearnaley DP, Syndikus I, Khoo V, et al
    The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
    Int J Radiat Oncol Biol Phys. 2018;100:1179-1189.
    PubMed     Abstract available


  212. THARMALINGAM H, Choudhury A
    Relapsing Prostate Cancer: Castrate or Cure?
    Int J Radiat Oncol Biol Phys. 2018;100:1095-1096.
    PubMed    


  213. ONG WL, Evans S, Millar J
    In Regard to Yang et al.
    Int J Radiat Oncol Biol Phys. 2018;100:1294-1295.
    PubMed    


  214. SONG D
    Apply an Oligometastatic Paradigm for Nodal Recurrence.
    Int J Radiat Oncol Biol Phys. 2018;100:1098-1099.
    PubMed    


  215. MENDIRATTA P, Garcia J
    Androgen Deprivation Fortified.
    Int J Radiat Oncol Biol Phys. 2018;100:1098.
    PubMed    


  216. TRAN PT, Feng F, Ost P
    Live to SABR Another Day?
    Int J Radiat Oncol Biol Phys. 2018;100:1097.
    PubMed    


    March 2018
  217. BRENNER DJ, Hall EJ
    Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?
    Int J Radiat Oncol Biol Phys. 2018;100:871-873.
    PubMed    


  218. FONTEYNE V, Sarrazyn C, Swimberghe M, De Meerleer G, et al
    4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial.
    Int J Radiat Oncol Biol Phys. 2018;100:866-870.
    PubMed     Abstract available


  219. VOGELIUS IR, Bentzen SM
    Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials.
    Int J Radiat Oncol Biol Phys. 2018;100:858-865.
    PubMed     Abstract available


  220. SANDLER HM
    Role of Overall Treatment Time in the Management of Prostate Cancer Patients: How to Manage Unscheduled Treatment Interruptions.
    Int J Radiat Oncol Biol Phys. 2018;100:841-842.
    PubMed    


  221. MAINTA IC, Zilli T, Tille JC, De Perrot T, et al
    The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An (18)F-MISO PET-MRI Study.
    Int J Radiat Oncol Biol Phys. 2018 Mar 8. pii: S0360-3016(18)30476.
    PubMed     Abstract available


  222. VALICENTI RK, Pugh SL, Trabulsi EJ, Sartor O, et al
    First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2018;100:695-701.
    PubMed     Abstract available


    February 2018
  223. CYSOUW M, Bouman-Wammes E, Hoekstra O, van den Eertwegh A, et al
    Prognostic Value of [(18)F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Feb 13. pii: S0360-3016(18)30252.
    PubMed     Abstract available


  224. TANDBERG DJ, Oyekunle T, Lee WR, Wu Y, et al
    Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
    Int J Radiat Oncol Biol Phys. 2018 Feb 8. pii: S0360-3016(18)30248.
    PubMed     Abstract available


  225. KEALL PJ, Colvill E, O'Brien R, Caillet V, et al
    Electromagnetic-Guided MLC Tracking Radiation Therapy for Prostate Cancer Patients: Prospective Clinical Trial Results.
    Int J Radiat Oncol Biol Phys. 2018 Feb 6. pii: S0360-3016(18)30222.
    PubMed     Abstract available


  226. AKSNESSAETHER BY, Solberg A, Klepp OH, Myklebust TA, et al
    Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?
    Int J Radiat Oncol Biol Phys. 2018 Feb 5. pii: S0360-3016(18)30220.
    PubMed     Abstract available


  227. WILKINS AC, Gusterson B, Szijgyarto Z, Haviland J, et al
    Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Feb 3. pii: S0360-3016(18)30186.
    PubMed     Abstract available


  228. GRAFF P, Portalez D, Lusque A, Brun T, et al
    IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Feb 2. pii: S0360-3016(18)30180.
    PubMed     Abstract available


  229. DORTH JA, Lee WR, Chino J, Abouassaly R, et al
    Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018;100:383-390.
    PubMed     Abstract available


    January 2018
  230. DESS RT, Devasia TP, Aghdam N, Jackson WC, et al
    Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Jan 31. pii: S0360-3016(18)30127.
    PubMed     Abstract available


  231. YANG DD, Muralidhar V, Mahal BA, Nguyen PL, et al
    Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2018;100:53-58.
    PubMed     Abstract available


  232. ROMESSER PB, Pei X, Shi W, Zhang Z, et al
    Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
    Int J Radiat Oncol Biol Phys. 2018;100:59-67.
    PubMed     Abstract available


  233. JOHNSTONE E, Wyatt JJ, Henry AM, Short SC, et al
    Systematic Review of Synthetic Computed Tomography Generation Methodologies for Use in Magnetic Resonance Imaging-Only Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2018;100:199-217.
    PubMed     Abstract available


  234. QIN N, Shen C, Tsai MY, Pinto M, et al
    Full Monte Carlo-Based Biologic Treatment Plan Optimization System for Intensity Modulated Carbon Ion Therapy on Graphics Processing Unit.
    Int J Radiat Oncol Biol Phys. 2018;100:235-243.
    PubMed     Abstract available


  235. CHI MS, Yang KL, Chang YC, Ko HL, et al
    Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2018;100:78-87.
    PubMed     Abstract available


    December 2017
  236. VIGNEAULT E, Martell K, Taussky D, Husain S, et al
    Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?
    Int J Radiat Oncol Biol Phys. 2017 Dec 28. pii: S0360-3016(17)34499.
    PubMed     Abstract available


  237. MCCLELLAND S 3RD, Jaboin JJ, Mitin T
    Is Advocacy for Active Surveillance Over Definitive Intervention in Low-Risk Prostate Cancer Applicable to African American Patients?
    Int J Radiat Oncol Biol Phys. 2017;99:1076-1077.
    PubMed    


  238. WORTEL RC, Heemsbergen WD, Smeenk RJ, Witte MG, et al
    Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels.
    Int J Radiat Oncol Biol Phys. 2017;99:1243-1252.
    PubMed     Abstract available


  239. WADDLE MR, Sio TT, Van Houten HK, Foote RL, et al
    Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients.
    Int J Radiat Oncol Biol Phys. 2017;99:1078-1082.
    PubMed     Abstract available


    November 2017
  240. YANG DD, Muralidhar V, Nguyen PL, Buzurovic I, et al
    Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;99:904-911.
    PubMed     Abstract available


  241. KOONTZ BF
    Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet.
    Int J Radiat Oncol Biol Phys. 2017;99:761-763.
    PubMed    


  242. VAN DER VELDEN JM, Peters M, Verlaan JJ, Versteeg AL, et al
    Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases.
    Int J Radiat Oncol Biol Phys. 2017;99:859-866.
    PubMed     Abstract available


  243. LIM-REINDERS S, Keller BM, Al-Ward S, Sahgal A, et al
    Online Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2017;99:994-1003.
    PubMed     Abstract available


  244. BARADARAN-GHAHFAROKHI M, Amouheidari A, Shahbazi-Gahrouei D, Baradaran-Ghahfarokhi HR, et al
    Evaluation of the Effects of Prostate Radiation Therapy on Occludin Expression and Ultrasonography Characteristics of the Bladder.
    Int J Radiat Oncol Biol Phys. 2017;99:963-971.
    PubMed     Abstract available


  245. MARTELL K, Husain S, Taussky D, Angyalfi S, et al
    Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.
    Int J Radiat Oncol Biol Phys. 2017;99:895-903.
    PubMed     Abstract available


  246. GUPTA SK, Watson T, Denham J, Shakespeare TP, et al
    Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
    Int J Radiat Oncol Biol Phys. 2017;99:701-709.
    PubMed     Abstract available


  247. DATTA NR, Stutz E, Rogers S, Bodis S, et al
    Conventional Versus Hypofractionated Radiation Therapy for Localized or Locally Advanced Prostate Cancer: A Systematic Review and Meta-analysis along with Therapeutic Implications.
    Int J Radiat Oncol Biol Phys. 2017;99:573-589.
    PubMed     Abstract available


  248. CHOUDHURY A
    ProtecTing Low-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;99:515-517.
    PubMed    


  249. BERLIN A, Ahmad AE, Chua MLK, Moraes FY, et al
    Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-Front Radical Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Nov 1. pii: S0360-3016(17)34048.
    PubMed     Abstract available


    October 2017
  250. ADJEIWAAH M, Bylund M, Lundman JA, Karlsson CT, et al
    Quantifying the Effect of 3T Magnetic Resonance Imaging Residual System Distortions and Patient-Induced Susceptibility Distortions on Radiation Therapy Treatment Planning for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Oct 20. pii: S0360-3016(17)34027.
    PubMed     Abstract available


  251. FRANK SJ, Pugh TJ, Blanchard P, Mahmood U, et al
    Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes.
    Int J Radiat Oncol Biol Phys. 2017 Oct 12. pii: S0360-3016(17)33968.
    PubMed     Abstract available


  252. ECHEVARRIA MI, Naghavi AO, Abuodeh YA, Ahmed KA, et al
    Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.
    Int J Radiat Oncol Biol Phys. 2017;99:378-382.
    PubMed     Abstract available


  253. PINKAWA M, Berneking V, Schlenter M, Krenkel B, et al
    Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results.
    Int J Radiat Oncol Biol Phys. 2017;99:374-377.
    PubMed     Abstract available


    September 2017
  254. KEAM SP, Caramia F, Gamell C, Paul PJ, et al
    The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort.
    Int J Radiat Oncol Biol Phys. 2017 Sep 25. pii: S0360-3016(17)33937.
    PubMed     Abstract available


  255. KERSHAW L, van Zadelhoff L, Heemsbergen W, Pos F, et al
    Image Guided Radiation Therapy Strategies for Pelvic Lymph Node Irradiation in High-Risk Prostate Cancer: Motion and Margins.
    Int J Radiat Oncol Biol Phys. 2017 Sep 8. pii: S0360-3016(17)33841.
    PubMed     Abstract available


  256. PICKLES T, Tyldesley S, Hamm J, Virani SA, et al
    Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.
    Int J Radiat Oncol Biol Phys. 2017 Sep 4. pii: S0360-3016(17)33839.
    PubMed     Abstract available


  257. DAYES IS, Parpia S, Gilbert J, Julian JA, et al
    Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate.
    Int J Radiat Oncol Biol Phys. 2017;99:90-93.
    PubMed     Abstract available


  258. SUJENTHIRAN A, Nossiter J, Charman SC, Parry M, et al
    National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Sep 1. pii: S0360-3016(17)33654.
    PubMed     Abstract available


    August 2017
  259. AGGARWAL A, Lewis D, Sujenthiran A, Charman SC, et al
    Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study.
    Int J Radiat Oncol Biol Phys. 2017 Aug 24. pii: S0360-3016(17)33774.
    PubMed     Abstract available


  260. REIS FERREIRA M, Khan A, Thomas K, Truelove L, et al
    Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Aug 2. pii: S0360-3016(17)33655.
    PubMed     Abstract available


  261. MALLA B, Zaugg K, Vassella E, Aebersold DM, et al
    Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2017;98:982-995.
    PubMed     Abstract available


  262. GLASER SM, Chen KS, Benoit RM, Smith RP, et al
    Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131.
    Int J Radiat Oncol Biol Phys. 2017;98:1053-1058.
    PubMed     Abstract available


  263. WANG C, Kishan AU, Kamrava M, Steinberg ML, et al
    External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Int J Radiat Oncol Biol Phys. 2017;98:1045-1052.
    PubMed     Abstract available


  264. BEN-JOSEF AM, Chen J, Wileyto P, Doucette A, et al
    Effect of Eischens Yoga During Radiation Therapy on Prostate Cancer Patient Symptoms and Quality of Life: A Randomized Phase II Trial.
    Int J Radiat Oncol Biol Phys. 2017;98:1036-1044.
    PubMed     Abstract available


    July 2017
  265. FANG P, He W, Gomez DR, Hoffman KE, et al
    Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
    Int J Radiat Oncol Biol Phys. 2017;98:748-757.
    PubMed     Abstract available


  266. MIDDELBURG JG, Mast ME, de Kroon M, Jobsen JJ, et al
    Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity in Elderly Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2017;98:843-849.
    PubMed     Abstract available


  267. SONG YP, Ellis T, Walshaw R, Mbanu P, et al
    Comparing Clinical Outcomes for Radium-223: Do Older Patients Do Worse?
    Int J Radiat Oncol Biol Phys. 2017;98:955-957.
    PubMed     Abstract available


  268. WAHL DR, Nguyen PL, Santiago M, Yousefi K, et al
    Pan-Cancer Analysis of Genomic Sequencing Among the Elderly.
    Int J Radiat Oncol Biol Phys. 2017;98:726-732.
    PubMed     Abstract available


  269. MOROTE J, Tabernero AJ, Alvarez Ossorio JL, Ciria JP, et al
    Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study.
    Int J Radiat Oncol Biol Phys. 2017;98:590-594.
    PubMed     Abstract available


  270. RODDA S, Morris WJ, Hamm J, Duncan G, et al
    ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;98:581-589.
    PubMed     Abstract available


  271. CORKUM MT
    Prostate Cancer With Isolated Bony Metastasis: Sternal Struggle.
    Int J Radiat Oncol Biol Phys. 2017;98:492-493.
    PubMed    


  272. SIVA S
    Prostate-Specific Membrane Antigen PET Before Aggressive Local Therapy to the Sternum.
    Int J Radiat Oncol Biol Phys. 2017;98:494-495.
    PubMed    


    June 2017
  273. DADKHAH H, Hopfensperger KM, Kim Y, Wu X, et al
    Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Jun 20. pii: S0360-3016(17)31057.
    PubMed     Abstract available


  274. SHENG Y, Li T, Lee WR, Yin FF, et al
    Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis.
    Int J Radiat Oncol Biol Phys. 2017;98:473-480.
    PubMed     Abstract available


  275. YANG DD, Muralidhar V, Mahal BA, Labe SA, et al
    National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;98:338-343.
    PubMed     Abstract available


  276. O'CALLAGHAN ME, Raymond E, Campbell JM, Vincent AD, et al
    Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.
    Int J Radiat Oncol Biol Phys. 2017;98:318-337.
    PubMed     Abstract available


  277. LAWTON CAF, Lin X, Hanks GE, Lepor H, et al
    Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
    Int J Radiat Oncol Biol Phys. 2017;98:296-303.
    PubMed     Abstract available


  278. SPRATT DE, Jagsi R
    Breast and Prostate Cancer: Lessons to Be Shared.
    Int J Radiat Oncol Biol Phys. 2017;98:263-268.
    PubMed    


  279. CHARGARI C, Haie-Meder C, Guerin F, Minard-Colin V, et al
    Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma.
    Int J Radiat Oncol Biol Phys. 2017;98:352-359.
    PubMed     Abstract available


  280. GAY HA, Sanda MG, Liu J, Wu N, et al
    External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
    Int J Radiat Oncol Biol Phys. 2017;98:304-317.
    PubMed     Abstract available


    May 2017
  281. HAUCK CR, Ye H, Chen PY, Gustafson GS, et al
    Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;98:108-114.
    PubMed     Abstract available


  282. GESTAUT MM, Cai W, Vyas S, Patel BJ, et al
    Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;98:101-107.
    PubMed     Abstract available


  283. CHEN WS, Townsend JP, Yu JB
    Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets.
    Int J Radiat Oncol Biol Phys. 2017;98:8-10.
    PubMed    


    April 2017
  284. KANOUN S, Walker P, Vrigneaud JM, Depardon E, et al
    18F-Choline Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for the Detection of Early Local Recurrence of Prostate Cancer Initially Treated by Radiation Therapy: Comparison With Systematic 3-Dimensional
    Int J Radiat Oncol Biol Phys. 2017;97:986-994.
    PubMed     Abstract available


  285. CIEZKI JP, Weller M, Reddy CA, Kittel J, et al
    A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk
    Int J Radiat Oncol Biol Phys. 2017;97:962-975.
    PubMed     Abstract available


  286. YOSHIOKA Y, Kotsuma T, Komiya A, Kariya S, et al
    Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;97:952-961.
    PubMed     Abstract available


  287. BOSCO C, Garmo H, Adolfsson J, Stattin P, et al
    Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events.
    Int J Radiat Oncol Biol Phys. 2017;97:1026-1031.
    PubMed     Abstract available


  288. SCHILD MH, Schild SE, Wong WW, Vora SA, et al
    A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT.
    Int J Radiat Oncol Biol Phys. 2017;97:1021-1025.
    PubMed     Abstract available


  289. REED A, Valle LF, Shankavaram U, Krauze A, et al
    Effect of Prostate Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy on Radiation Treatment Recommendations.
    Int J Radiat Oncol Biol Phys. 2017;97:947-951.
    PubMed     Abstract available


  290. HAMSTRA DA, Mariados N, Sylvester J, Shah D, et al
    Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
    Int J Radiat Oncol Biol Phys. 2017;97:976-985.
    PubMed     Abstract available


    March 2017
  291. SIMON A, Le Maitre A, Nassef M, Rigaud B, et al
    Is Dose Deformation-Invariance Hypothesis Verified in Prostate IGRT?
    Int J Radiat Oncol Biol Phys. 2017;97:830-838.
    PubMed     Abstract available


  292. NICOLAE A, Morton G, Chung H, Loblaw A, et al
    Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2017;97:822-829.
    PubMed     Abstract available


  293. MIKSYS N, Vigneault E, Martin AG, Beaulieu L, et al
    Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2017;97:606-615.
    PubMed     Abstract available


  294. PARKER WP, Evans JD, Stish BJ, Park SS, et al
    Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.
    Int J Radiat Oncol Biol Phys. 2017;97:526-535.
    PubMed     Abstract available


    February 2017
  295. YAHYA N, Ebert MA, House MJ, Kennedy A, et al
    Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface.
    Int J Radiat Oncol Biol Phys. 2017;97:420-426.
    PubMed     Abstract available


  296. MISHRA MV, Aggarwal S, Bentzen SM, Knight N, et al
    Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials.
    Int J Radiat Oncol Biol Phys. 2017;97:228-235.
    PubMed     Abstract available


  297. PISANSKY TM, Tendulkar RD
    In Reply to Ghadjar et al.
    Int J Radiat Oncol Biol Phys. 2017;97:439-440.
    PubMed    


    January 2017
  298. RODDA S, Tyldesley S, Morris WJ, Keyes M, et al
    ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Jan 6. pii: S0360-3016(17)30008.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: